Background: Diabetes is a risk factor for atherosclerotic disease but negatively associated with the development and progression of abdominal aortic aneurysm (AAA). Advanced glycation end products (AGEs) are increased in diabetes and renders the vascular matrix more resistant to proteolysis. We assessed the concentration of AGEs in AAA biopsies obtained from diabetic and nondiabetic patients and hypothesized that (nonenzymatic) glycation of AAA tissue protects against proteolytic breakdown of collagen. Methods: AAA biopsies were collected from 30 diabetic and 30 matched nondiabetic AAA patients at the time of open repair. Aortic control samples from 10 nondiabetic and 16 diabetic patients were collected, and concentrations of the AGE cross-link pentosidine was measured. Furthermore, noncross-linking AGEs (adducts), as well as proteolytic enzymes known to play a role in aneurysm development (matrix metalloproteinase [MMP]-2, MMP-9, cathepsin B and S) were quantified. Ex vivo, nondiabetic AAA biopsies were glycated and measured subsequently for collagen type I release. Results: Pentosidine concentrations in AAA wall biopsies were increased in patients with diabetes compared with nondiabetics 9.4 (5.0-13.5) vs 6.0 (2.5-9.6) pmol/mmol lysine (P [ .02). Increased pentosidine concentrations were also observed in nonaneurysmatic aortic wall biopsies from diabetic patients. In diabetic AAA vascular wall tissue, pentosidine concentration was negatively correlated with aortic diameter (r [ L0.43; P [ .02). Ex vivo glycated AAA biopsies were
Abdominal aortic aneurysm (AAA) is defined as a permanent dilatation of the abdominal aorta and is causally related with 1.3% of all deaths among men aged 65 to 85 years in developed countries. 1 Expansion of the aortic diameter is accompanied with an increased risk of aortic rupture. [2] [3] [4] [5] The risk for AAA development is associated with the presence of atherosclerotic disease. However, patients suffering from diabetes, one of the most established risk factors for atherosclerosis, seem to be protected against the development and progression of AAA. This observation was first noticed in 1995 in the Aneurysm Detection and Management (ADAM) study by Lederle et al. 6 This have been confirmed in a variety of subsequent studies that reported a prevalence of diabetes in studied patients with AAA that ranged from 6% to 14%, whereas in control patients without AAA this number ranged from 17% to 36%. Pooled analyses of these studies demonstrated reduced odds of diabetes in patients with AAA disease. 7, 8 Supportive for the concept that diabetes is a protective factor is the observation that AAA growth rates are significantly slower in diabetic patients compared with nondiabetic patients. [9] [10] [11] [12] In addition, a reduced incidence of AAA rupture in patients with diabetes has been observed compared with patients without diabetes. 5, 13 The mechanism of the negative association between diabetes and AAA progression is unknown. 8, 14 In animal models, hyperglycemia was associated with slower AAA growth, and insulin therapy diminished this effect. 15 Advanced glycation end products (AGEs) are increased in diabetes and render the vascular matrix more resistant to proteolysis. 10, 14 AGEs form a heterogeneous group of glycated proteins and include noncross-linking AGEs such as carboxymethyllysine (CML), carboxyethyllysine (CEL), and cross-linking AGEs. 16 One of the best characterized cross-linking AGEs, is pentosidine, a fluorescent crosslink between arginine and lysine. Several studies reported decreased collagen degradation by collagenase in artificially glycated tissues with high pentosidine levels in vitro. 17, 18 In the present study, we assessed the concentration of AGEs in AAA biopsies obtained from diabetic and nondiabetic patients and hypothesized that glycation of AAA tissue protects against proteolytic breakdown of collagen.
METHODS
Aneurysm-Express biobank. Aneurysm-Express is an ongoing longitudinal vascular biobank study. 19 All patients undergoing open AAA repair in two Dutch hospitals are asked to participate in the study. The Medical Ethics Committees of both hospitals approved the study and participants provided written informed consent. For the current investigation, we studied the ventral AAA wall biopsies from consecutive diabetic patients who were included between April 2003 and April 2011.
Patient population. Consecutive diabetic patients undergoing open repair of asymptomatic AAA were included. The diabetic AAA patients who donated tissue to the biobank (n ¼ 30) were matched with nondiabetic AAA patients (n ¼ 30). The indications for intervention were based on current guidelines and included AAA diameter exceeding 55 mm for males, and AAA diameters between 50 and 55 mm for females. 20 Patients with AAA diameters between 50 and 55 mm were selected for surgery based on the clinical judgment of the surgeon and in consultation with the patient. Open repair was performed in patients in whom AAAs were not suited anatomically to endovascular repair.
Nonaneurysmatic aortic samples were collected from the infrarenal region in postmortem age-matched patients and served as controls. We collected 10 nonaneurysmatic aortic samples from different postmortem patients without diabetes, and 16 nonaneurysmatic aortic samples from different postmortem patients with diabetes.
Baseline characteristics. All baseline characteristics were obtained from clinical records and questionnaires at the time of recruitment. These questionnaires included history of vascular disease, cardiovascular risk factors (age, diabetes, gender, hypertension, smoking), and medication use. Aortic diameter and morphology were assessed via computed tomography angiography. Diabetes mellitus was defined as use of insulin or oral hypoglycemic agents. Hypertension was defined as systolic blood pressure of greater than 140 mm Hg or use of blood pressurelowering drugs; smoking was defined on the basis of whether patients had smoked during the last weeks before AAA surgery. Kidney function was estimated using creatinine concentrations (mmol/L) from venous blood drawn at baseline before AAA surgery.
Blood and tissue sampling. Biopsies of the ventral wall from the AAA at the site of maximal diameter were collected during open repair and dissected into 5-mm segments. The middle segment was fixed in 4% formaldehyde, decalcified for 1 week in ethylenediaminetetraacetic acid and embedded in paraffin. Adjacent segments were snap-frozen in liquid nitrogen, ground, and extracted in 1.5 mL of 40 mmol Tris/HCl. Total protein concentration of every sample was quantified via a BCA protein measurement method (Pierce Biotechnology, Rockford, Ill). Aqueous isolates and pellets with crosslinked proteins from ground AAA segments were stored at À80
C. Arterial blood samples from 15 AAA patients with and without diabetes were available and collected before surgery. Blood samples were centrifuged at 1850 Â g for 10 minutes. Plasma was collected and stored at À80 C in 0.5-mL tubes.
Pentosidine measurements by high-performance liquid chromatography. Pentosidine concentrations were determined as described previously, 21 by reversed phase high-performance liquid chromatography (HPLC)-fluorescence using an Allsphere ODS-2 (150 mm Â 4.6 mm, 3 mm) precolumn (Alltech/Grace, Breda, The Netherlands). Detection was performed using a Jasco type 821-FP spectrofluormeter (Jasco Benelux, Maarssen, The Netherlands) set at excitation and emission wavelengths of 325 and 385 nm, respectively. HPLC analysis was performed using a binary high-pressure gradient at a flow of 1 mL/min using two Model PU-980 pumps (Jasco Benelux). Solvent A was 25 mmol/L citric acid and solvent B was (50/50, v/v) ACN/25 mmol/L citric acid. A linear gradient was started at 99% solvent A, which was changed within 15 minutes to 90% solvent A. After cleaning the column with 100% solvent B for 5 minutes, the column was equilibrated for 8 minutes at the initial composition. Injection volume was 10 mL and column temperature was set at 20 C using a Spark Mistral column oven (Spark Holland B.V., Emmen, The Netherlands). Samples were thermostatted at 6 C using an autoinjector model 717 Plus Autosampler (Waters, Etten Leur, The Netherlands). Chromatograms were acquired and processed with Totalchrom (PerkinElmer, version 6.2.0.0.0: B27, Zoetermeer, The Netherlands).
Stored protein pellets from the AAA-express biobank were hydrolyzed by adding 2 mL 6N HCl and incubated for 24 hours in a 10-mL glass tube with a Teflon-lined screw cap at 100 C. After hydrolysis, samples were evaporated to dryness at 80 C under a stream of nitrogen gas and reconstituted in 200 mL 25 mmol/L citric acid/L. This solution was centrifuged for 15 minutes (4 C) at 14,000 rpm. Ten microliters of this solution was injected on the HPLC system. Pentosidine concentration was expressed as pmol/mmol lysine in hydrolysates. All measured concentrations were related to the amount of lysine detected in every sample.
Measurement of noncross-linking AGEs CML, CEL, by stable-isotope-dilution tandem mass spectrometry. CML and CEL concentrations were determined as described previously, 22 by an API 3000 triple-quadrupole tandem mass spectrometer (SciexApplied Biosystems, Foster City, Calif) interfaced with a TurboIonSpray source. The LC system consisted of a Series 200 autosampler, a Series 200 quaternary pump, and a Series 200 inline degasser (Perkin-Elmer, Norwalk, Conn). Mass spectra were acquired and processed with Analyst, Ver. 1.3.1, software (Sciex-Applied Biosystems). Mass spectrometry conditions were optimized by direct infusion of analytes into the mass spectrometer source with a syringe pump from Harvard Apparatus.
Samples were analyzed at ambient temperature by reversed-phase HPLC on a Symmetry C18 column (3.9 150 mm; 5-m particle size; Waters) with NFPA as the ion pairing agent. Mobile phase A consisted of aqueous NFPA (5 mmol/L), and mobile phase B was acetonitrile. Compounds were eluted with a linear gradient from 10% to 25% B in 10 minutes. Thereafter, strongly retained compounds were removed from the column by a strong solvent wash: between 10 and 12 minutes, mobile phase B was increased to 80% and maintained at this percentage until 14 minutes. Between 14 and 16 minutes, the percentage of mobile phase B was reduced to initial conditions and maintained at this percentage for 5 minutes to equilibrate the column before the next injection at 21 minutes.
The injection volume was 10 mL. The flow rate was 1 mL/min, and 20% of the column effluent was introduced into the ion spray source of the tandem mass spectrometer by means of a postcolumn T-piece. Analyses were performed in positive ion mode. The ion spray voltage was set at 4500 V, and the declustering and focusing potentials were set at 20 and 240 V, respectively. The temperature of the turbo ion gas was 500 C. Each mass transition was monitored for 150 ms with a 5-ms interchannel delay time, giving a cycle time of 930 ms. For both CML and CEL, the product ion at m/z 84.1 was used for quantification and the product ion at m/z 130.1 for confirmation. In each series, five calibration samples spanning the concentration ranges of 0 to 2.5 mol/L for CML and 0 to 1.0 mol/L for CEL were included. Calibration curves for CML and CEL, obtained by linear regression of a plot of the analyte/internal standard peak area ratio vs analyte concentration, were used to calculate concentrations in plasma samples. Both low-and high-concentration quality control samples were included in each analytical series.
Ex vivo glycation of AAA biopsies and collagen type I degradation. AAA biopsies were obtained from AAA patients without diabetes. Biopsies (n ¼ 4) were decellularized by a freeze-thaw cycle to exclude cellular effects. Each AAA tissue was divided into two segments, one segment for ex vivo glycation; one segment served as a control. The dry weight value of each segment was obtained. AAA tissue was incubated with 350 mmol/L ribose (R-7500 sigma; D-(-)-Ribose) and 5 mmol/L threose (T-7642 sigma; L-(þ)-threose) in phosphate-buffered saline (PBS) for 4 days at 37 C. Free ribose and threose were washed out with PBS (3 times for 1 hour at 37 C). Nonglycated AAA tissue was incubated with PBS for 4 days at 37 C. Subsequently, AAA tissue was incubated in PBS (8 days at 37 C) to allow early glycation products to mature into AGEs. Nonglycated AAA tissue followed the same protocol. Penicillin and streptomycin were added to the incubation solutions to prevent contamination. To determine whether glycation was successful, CML, CEL, and pentosidine concentrations were measured from the glycated tissues.
Carboxyterminal telopeptides of collagen type I (ICTPs) are released during the degradation of mature type I collagen by matrix metalloproteinases (MMPs), and are a measure for collagen type I breakdown. For the detection of ICTP, glycated and nonglycated AAA segments were divided in two parts. One part was incubated with 200 mL Clostridium histolyticum collagenase (CLS 2; Worthington, Freehold, NJ) for 4 days at 37
C. The other part, which served as a control, was incubated with PBS for 4 days at 37
C. ICTP amounts in the removed supernatant from processed AAA tissues were quantified by an enzyme-linked immunoassay (UniQ ICTP; Orion Diagnostica, Espoo, Finland).
Cysteine proteinases form a different enzymatic pathway to degrade collagen type I. During the degradation of mature collagen type I by cysteine proteinases, particularly cathepsin K, collagen type I C-telopeptide (CTx) fragments are released. CTx fragments in the removed supernatant from processed AAA tissues were quantified with an enzyme-linked immunosorbent assay kit (CTxI, Uscn, China). All measured concentrations were related to the dry weight value of each segment. A flowchart of the ex vivo experiment is shown in Supplementary Fig 1 (online only) .
AAA biopsy characterization by immunohistochemistry. The paraffin-embedded segment of the AAA biopsy was cut into 4-mm sections. Infiltration of macrophages, T lymphocytes, B lymphocytes, and plasma cells (CD-68, CD3, CD20, and CD138), vascular smooth muscle cells (a-smooth muscle actin), the amount of collagen (Picro-Sirius red), elastin (elastin von Giesson), and calcification (hematoxylin and eosin) were semiquantitatively scored as no, minor, moderate, or heavy staining as described previously. 19 Histologic examination was performed by two independent observers (R.H., A.V.) unaware of the clinical data. In case of discrepancies in judgment, sections were reanalyzed. Consensus was reached in all cases. Furthermore, MMP-2 and MMP-9 were measured using Biotrak activity assays (Amersham Biosciences, GE Healthcare, Hertfordshire, UK). The assays used recognizes the pro and active forms of MMPs. It does not cross-react with other MMPs or tissue inhibitor of metalloproteinases.
Statistical analysis. SPSS 15.0 (SPSS, Chicago, Ill) was used for all statistical analyses. Continuous variables were given as median with interquartile range. Discrete variables were reported as number and percentages.
Mann-Whitney tests, Kruskal-Wallis test, c 2 , and Spearman correlation analysis were conducted as appropriate. The association of pentosidine concentrations with AAA diameter was further investigated using the receiver operating characteristic curve and area under the curve. The paired t-test was used for the performed ex vivo experiments because the segments that were compared were related. All tests were two sided, with P < .05 considered significant. We matched diabetic patients with nondiabetic patients for age, gender, AAA diameter, kidney function, and smoking habits. These variables were chosen because they might influence the concentrations of AGEs in AAA vessel walls apart from diabetes.
RESULTS
Baseline characteristics. AAA biopsies were collected from 60 AAA patients at open surgery. The study cohort consisted of 30 diabetics, and 30 matched nondiabetic AAA patients. As shown in Table I , no differences for the documented baseline characteristics between nondiabetic and diabetic patients were observed. In AAA patients with diabetes, 7 (23.3%) used insulin, 20 (66.7%) used metformin, and 3 (10.0%) used either tolbutamide, glimepiride, or gliclazide as oral hypoglycemic agents. The median glucose concentration was 6.6 mmol/L.
Noncross-linked AGEs and cross-linked AGEs in AAA biopsies. In AAA tissues no differences were observed between diabetics and nondiabetics in the noncrosslinking AGEs CML and CEL (Fig 1, A and B) . However, the cross-linking AGE pentosidine was increased significantly in AAA patients with diabetes compared with nondiabetics (lysine: median, 9.4 pmol/mmol [interquartile range, 5.0-13.5] vs 6.0 [2.5-9.6], respectively; ¼ .02; Fig 1, C) .
Nonaneurysmatic aortic biopsies had pentosidine concentrations of 14.7 pmol/mmol (6.9-39.6) compared with the median pentosidine concentrations of 7.4 pmol/ mmol (3.1-15.0) lysine in AAA biopsies (P < .001).
Furthermore, in nonaneurysmatic aortic biopsies increased tissue concentrations were observed in diabetic samples compared with nondiabetic samples for CML, CEL, and pentosidine (Fig 2, A-C) .
Pentosidine concentrations tended towards a negative correlation with AAA diameter (r ¼ À0.23; P ¼ .08) in all AAA patients. When AAA patients with diabetes were analyzed separately, a significant negative association of pentosidine concentrations with AAA diameter was observed (r ¼ À0.43; P ¼ .02; Fig 3) . The area under the curve (95% confidence interval) of pentosidine for discriminating an AAA diameter larger than 60 mm was 0.71 (0.51-0.90), as calculated with the receiver operator curve. The group of nondiabetic patients suffering from AAA showed no association between the concentration of pentosidine and AAA diameter (r ¼ À0.05; P ¼ .79). There was no correlation between tissue pentosidine or glucose concentrations in blood (r ¼ 0.014; P ¼ .96).
Effect of glycation of AAA tissue on ICTP and collagen type I CTx release ex vivo. ICTP are released during the degradation of mature type I collagen by MMPs and are a measure for collagen type I breakdown.
Incubation of human AAA tissue from patients without diabetes with ribose and threose resulted in decreased collagenase-induced release of ICTP fragments, which supports the concept that glycated collagen networks are protected from proteolysis by MMPs (Fig 4, A) . When we compared glycated biopsies and nonglycated AAA biopsies from the same patient, we observed a decreased concentration of released ICTP in every sample after glycation (Fig 4, B) .
We also tested whether ex vivo glycated AAA tissue was protected from the cysteine protease induced degradation of collagen type I. Glycated AAA tissue demonstrated lower concentrations of CTx release, but this difference was not significant (Fig 5, A, B) . All tissues incubated in PBS showed minimal collagen type I degradation and served as negative controls. Glycation of AAA biopsies was successful; a significant increase in AGEs was observed in the glycated samples.
AGEs in blood plasma from AAA patients. Given the significant difference of pentosidine concentration in AAA biopsies between nondiabetic and diabetic patients, we assessed whether circulating concentrations of pentosidine were different between AAA patients with and without diabetes. We measured plasma concentrations of pentosidine in 15 nondiabetic and 15 diabetic patients with AAA. Plasma concentrations of pentosidine did not differ between nondiabetic 0.52 nmol/mmol lysine (0.47-0.69), and diabetic patients nmol/mmol lysine 0.69 (0.49-0.82; P ¼ .25). Plasma concentrations of pentosidine were not correlated with AAA diameter (r ¼ À0.02; P ¼ .94; n ¼ 30). Furthermore, plasma concentrations of pentosidine were not associated with pentosidine concentrations in AAA biopsies (r ¼ 0.08; P ¼ .70; n ¼ 30). Plasma concentrations of CML and CEL in plasma were not different between AAA patients with diabetes and AAA patients without diabetes (data not shown). 
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MMP, cytokine, and cathepsin expression in diabetic AAAs. MMP activity might be inhibited by diabetes mellitus, which could explain the observed decreased collagen breakdown in diabetic AAA samples. To investigate whether lower activity of proteolytic enzymes could be confounding factors for the relationship between pentosidine concentration and aneurysm diameter in AAA patients with diabetes, we assessed MMP-2 and MMP-9 activity in AAA biopsies. Furthermore, cathepsin A, B, and S, and interleukin-6 and interleukin-8 expression from AAA biopsies were analyzed. No differences in protease activity or interleukin and protease expression were observed between nondiabetic and diabetic AAA patients (Table II) . A subgroup analysis was performed in AAA diabetics with low vs high pentosidine concentrations (Table III) . No differences in inflammation between the groups were observed. The concentration of pentosidine in AAA biopsies was not associated with any inflammatory or proteolytic marker of AAA severity (data not shown). Histologic differences in nondiabetic and diabetic AAA biopsies. We examined histologic sections of nondiabetic and diabetic AAA patients. Histology grading of AAA biopsies revealed no differences in elastin or collagen content. Staining for different cell types of the inflammatory infiltrate in AAA biopsies showed no differences. However, increased staining for vascular smooth muscle cells was observed in nondiabetic patients (P ¼ .02). The relations between diabetes and histologic characteristics of AAA biopsies are shown in Supplementary Fig 2 (online only) .
DISCUSSION
The current study shows an increased aortic wall concentration of pentosidine in AAA patients with diabetes compared with nondiabetics. Pentosidine concentration was correlated negatively with aortic diameter in diabetic AAA patients. Ex vivo, we observed that glycation of AAA tissue protected against MMP-induced collagen type I degradation. However, glycation of AAA tissue did not protect against cysteine protease-induced collagen type I degradation. No differences in inflammatory infiltrates and abundance were observed between nondiabetic and diabetic AAA patients. Furthermore, no difference in the expression of proteolytic enzymes was observed between the two groups.
In AAA disease, proteolytic activity is increased and the balance between matrix synthesis and degradation shifts toward matrix degradation, resulting in loss of aortic wall integrity and outward remodeling. 23, 24 A protective factor for AAA development and progression is diabetes. 7, 9, 11 In cardiovascular disease, diabetes is characterized by increased matrix volume, resulting in increased aortic intima media stiffness, and cardiac left ventricular mass. In atherosclerotic plaques, diabetes results in a more fibrous plaque type. 25, 26 Furthermore, diabetes results in increased basement membrane thickening and glomerulosclerosis. 27 Several studies have reported that AGE accumulation on matrix proteins is associated with increased resistance to proteolysis. 17, 18, 28 The current study showed that the cross-linking AGE pentosidine is increased in aortic biopsies from diabetic AAA patients compared with AAA patients without diabetes. In contrast, the expression of noncross-linking AGEs, CML, and CEL did not differ significantly between patient groups. CML and CEL concentrations might be influenced by oxidation processes that occur in AAA disease. 29, 30 Furthermore, we observed higher noncross-linked AGEs and pentosidine concentrations in nonaneurysmatic aortic controls, which is in line with previous observations of circulating AGEs in AAA patients and aortic controls. 31 However, it is difficult to compare nonaneurysmatic aortic samples with AAA diseased samples because inflammation state, tissue structure, and amount and type of cells differ substantially in aortic controls compared with advanced AAA samples. 23, 24 We can only speculate whether a decreased expression of cross-linked AGEs, such as pentosidine, is preceding AAA development because this research is hampered by the difficult comparison of control samples with advanced AAA samples owing to the lack of available human tissue in the different stages of disease.
To investigate the observed differences in pentosidine concentrations between AAA patients with and without diabetes, we examined the effect of glycation of AAA biopsies on collagen degradation. This ex vivo study showed that glycation of AAA tissue protects against MMP-induced collagen type I degradation. Several other studies reported that glycation of tissue resulted in decreased collagen degradation, which is in line with our observations. 17, 18 The mechanism by which cross-linking AGEs impair proteolysis is currently unknown. Structural modification of collagen through cross-links might play a role. Odetti et al 32 reported diabetes-induced ultrastructural changes in collagen fibrils. They showed with scanning force microscopy that diabetes or incubation with glucose induces an increase of interfibril crosslinks, leading to an increase in fibril diameter, an increased density of fibril packing, and merging of fibrils. In Alzheimer disease, protein cross-linking by AGE structures results in the formation of protease-resistant aggregates. 33, 34 Moreover, Viguet-Carrin et al 35 suggested a link between vertebral trabecular bone microarchitecture and the pentosidine cross-link profile. Pentosidine concentration was correlated with an increased trabecular number and connectivity density. 35 We know that nonenzymatic glycation (especially ribose) leads to conformational changes of its target proteins, modifying their properties. 1 We speculate that MMPs are less effective in cleaving the catalytic domain of cross-linked AGEs owing to the conformational change that occurs when a cross-link is glycated. Owing to impaired cleaving effectiveness of MMP the structural integrity on microscopic level might be better preserved (elasticity and structural collagen layers) and less fibrosis with its weaknesses could be the result. A proposed mechanism is shown in Supplementary Fig 3 (online only) . Glycation also stimulates collagen synthesis via protein kinase C and transforming growth factor-b upregulation. 36 However, we observed no increase in collagen deposition in diabetic AAA patients. Patients with advanced AAA disease show thickening of the aortic vessel wall, and therefore any link between collagen quantity and diabetes may be difficult to detect in the samples analyzed. Crosslinking AGEs might play a role in preserving the quality of the collagen network owing to fibril packing, increased resistance to proteolysis and thereby helping to preserve the normal collagen network. 32, 35, 37, 38 We observed an association of pentosidine concentration with aortic diameter in diabetic patients with AAA. Therefore, validation of this marker in a large cohort of diabetic AAA patients is desirable but difficult, because of the scarcity of such samples owing to the increasing role of endoluminal stenting.
AGEs can stimulate the receptor of AGEs. It has been reported that receptor of AGEs promotes AAA development by inducing MMP-9 expression in mice. 39 The current study showed no differences in noncross-linking AGEs, MMP-2, or MMP-9 activity between nondiabetic and diabetes patients with an advanced AAA. CML and CEL are also formed under influence of oxidation, and the high levels of oxidation observed in AAA disease might promote the formation of noncross-linking AGEs like CML and CEL at the same rate in nondiabetic and diabetic AAA patients. 29, 30 Therefore, we speculate that these oxidative noncross-linking AGEs stimulate receptor of AGEs in nondiabetic as much as in diabetic AAA patients. The results in this study suggest that glycated crosslinks such as pentosidine play a causal role in the observed negative association between diabetes and AAA growth. Therefore, we assessed whether pentosidine could be used as a biomarker in blood plasma. No correlation between plasma pentosidine and aortic pentosidine concentrations was observed. This implicates that pentosidine measured in blood plasma is not a strong biomarker for the prediction of AAA progression. Pentosidine is formed in many other tissues and this might influence the pentosidine concentration measured in blood.
In this study cohort, 66.7% of the AAA patients with diabetes used metformin as an oral hypoglycemic agent. In addition, 23.3% patients used insulin, and we do not know whether these patients used metformin before the use of insulin. Metformin is a biguanidine and inhibits the formation of cross-linked AGEs. 40, 41 Whether diabetic patients with metformin use have an increased expansion of their aortic diameter compared with diabetic patients without a history of metformin use is currently unknown in literature. A study to investigate the influence of metformin use on AAA growth in diabetic patients is warranted. Possible therapies might include glycation of tissue with ribose. Although systemic effects via medication are probably not desirable, more local therapy could be applied with the glycation of stentgraft with ribose. This might decrease the risk of anastomotic aneurysm formation.
We realize that the evidence showing that pentosidine cross-links protects against AAA formation or progression should be more compelling before making strong inferences regarding causality. Animal models with AAA formation and progression are scarce and difficult to reproduce, which limits the extrapolation of this observation to a longitudinal AAA initiation and progression study in an animal setting. Furthermore, most experimental AAA models are chemically or genetically induced, which may not recapitulate the pathogenesis of human AAA formation. We feel that the current observations in human pathologic specimen are relevant for the understanding of the disease. The relevance of the observation is underscored by the fact that a large AAA biobank is required to obtain sufficient numbers of diabetic AAA specimen. A possible limitation of the study is the lack of tissue inhibitor of metalloproteinases and plasminogen activator inhibitor type 1 measurements and its relation to MMPs. However, MMP activity was measured and therefore the possible effect of tissue inhibitor of metalloproteinases and plasminogen activator inhibitor type 1 are probably reflected in the measurements. We determined the amount of inflammation between both groups and did not find a difference. We did not analyze the proinflammatory M1 vs non inflammatory M2 ratio, which might be an interesting topic for future research. Another possible limitation are the characteristics of the control group of the postmortem patients.
Owing to anonymity regulations (Dutch law) we only knew whether these controls had type 2 diabetes or not.
CONCLUSIONS
AAA patients with diabetes have increased cross-linked pentosidine in aortic tissue compared with nondiabetic patients. Ex vivo glycation of AAA tissue protects against collagen type I degradation induced by MMPs. These findings suggest that a cross-linking AGE like pentosidine plays a protective role in AAA progression in diabetic patients.
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